Could vitamin d levels predict ITP treatment success?
NCT ID NCT07146555
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will measure vitamin D levels in 84 adults newly diagnosed with immune thrombocytopenia (ITP), a bleeding disorder. Researchers want to see if vitamin D levels are linked to how well patients respond to first-line steroid therapy. The goal is to gather knowledge, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand whether vitamin D levels affect how well ITP patients respond to steroid therapy.
- What could go wrong
- This is an observational study with no intervention, so it cannot prove cause and effect. Results may not lead to any change in treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 84 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients (\>18 years), both male and female, with newly diagnosed immune thrombocytopenia (ITP), recruited from hematology clinics
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria:1- Adult (age\>18 years) 2-Primary ITP. 3-Patients with ITP who received first line steroid therapy. Exclusion Criteria:1-Age less than18years 2-Secodary ITP 3-Patients with ITP on second line steroid therapy. 4-Chronic renal disease. 5-Chronic liver disease. 6-Malnutrition and malabsorption.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Immune thrombocytopenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World data may reveal which ITP treatments work best
- A diet tweak may boost platelets in a bleeding disorder
- Could vitamin d predict cervical cancer treatment success?
- Can a new drug calm the immune System's attack on blood cells?
- Double attack on blood disorder: could two drugs beat one for stubborn ITP?
- Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?